Veliparib (ABT-888)

For research use only.

Catalog No.S1004 Synonyms: NSC 737664

182 publications

Veliparib (ABT-888) Chemical Structure

CAS No. 912444-00-9

Veliparib (ABT-888, NSC 737664) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Veliparib increases autophagy and apoptosis. Phase 3.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 156 In stock
USD 120 In stock
USD 227 In stock
USD 370 In stock
USD 990 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Veliparib (ABT-888) has been cited by 182 publications

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Description Veliparib (ABT-888, NSC 737664) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Veliparib increases autophagy and apoptosis. Phase 3.
Features Increases the efficacy of common cancer therapies such as radiation and alkylating agents.
Targets
PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
2.9 nM(Ki) 5.2 nM(Ki)
In vitro

ABT-888 is inactive to SIRT2 (>5 μM). [1] ABT-888 inhibits the PARP activity with EC50 of 2 nM in C41 cells. [2] ABT-888 could decrease the PAR levels in both irradiated and nonirradiated H460 cells. ABT-888 also reduces clonogenic survival and inhibits DNA repair by PARP-1 inhibition in H460 cells. ABT-888 increases apoptosis and autophagy in H460 cells when combination with radiation. [3] ABT-888 also inhibits PARP activity in H1299, DU145 and 22RV1 cells and the inhibition is independent of p53 function. ABT-888 (10 μM) suppresses the surviving fraction (SF) by 43% in the clonogenic H1299 cells. ABT-888 shows effective radiosensitivity in oxic H1299 cells. Furthermore, ABT-888 could attenuate the SF of hypoxic-irradiated cells including H1299, DU145 and 22RV1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
C41 MmnKT4lv[XOnIFHzd4F6 NVnhdJBnOzBibXnu NY\XUYx1UW6qaXLpeIlwdiCxZjDQRXJROSC5aYToJGVEPTBib3[gNE4xODJizszN MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTh6OEe2NEc,OTl6OEi3OlA9N2F-
Jurkat MYTLbY5ie2ViQYPzZZk> NV7yUlNFQTZiaB?= NEK5d41FVVOR M3jkdWlvcGmkaYTpc44hd2ZiUFHSVFEh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIH;mJINmdGxidnnhZoltcXS7IIfpeIghTUN3MDDv[kA{KM7:TR?= M1PRO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OEWwNVk6Lz5{M{i1NFE6QTxxYU6=
Capan1 MnfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV23NkBp NXe1[GZWTE2VTx?= MnfIRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDCVmNCOiCpZX7lJI12fGG2ZXSgbJVu[W5iQ3HwZY4yKGOnbHzzJJdqfGhiSVO1NEBw\iB|OT63JO69VQ>? MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN7OEO4N{c,OjR|OUizPFM9N2F-
DT40 NF20cYVEgXSxdH;4bYMhSXO|YYm= NIS3RYI4OiCq NEfYdW5FVVOR NYLUemJvS3m2b4TvfIlkcXS7IHHnZYlve3RiY3jpZ4tmdiCEUlPBNk1l\W[rY3nlcpQhTFR2MDDj[Yxtew>? M371SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUKyOVg4Lz5{NEmyNlU5PzxxYU6=
ML-1 NI\t[HZCeG:ydH;0bYMhSXO|YYm= NW\ycZpGOi53IN88US=> NV74VYZkOjRiaB?= NV2zNng2TE2VTx?= MUTTfY5memerc4TpZ4FtdHliZX7oZY5k\XNiVGLBTWwucW6mdXPl[EBieG:ydH;zbZMhcW5iTVytNUBk\Wyucx?= NX;nbmFqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4PVUyOzVpPkK0PFk2OTN3PD;hQi=>
HCT-116 NWTER4RmU2mwYYPlJGF{e2G7 NEnsXYkxNjVizszN MmjuNlQhcA>? M2fHRXBCWlBiYXP0bZZqfHliZHXjdoVie2W| NFHSRow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C1OFIyOyd-MkOwOVQzOTN:L3G+
UM-SCC1 M3TNcGN6fG:2b4jpZ{BCe3OjeR?= NXywNpU6OTBizszN NHnCUZQzPCCq MYDS[YR2[2W|IITo[UBk\WyuII\pZYJqdGm2eR?= NV\FWZdbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5NVI3OjBpPkKxPVEzPjJyPD;hQi=>
FaDu M2fUS2N6fG:2b4jpZ{BCe3OjeR?= MmHaNVAh|ryP MkW4NlQhcA>? NVPvXZRJWmWmdXPld{B1cGViY3XscEB3cWGkaXzpeJk> MnvwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7MUK2NlAoRjJzOUGyOlIxRC:jPh?=
PC-3 NIDxV|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3DeXEyOCEQvF2= NFLhTJZKdmS3Y3XzJIEhe2mpbnnmbYNidnRiaX7obYJqfGmxbjDpckBkd2yxbomg[o9zdWG2aX;uxsA> NYHRZmt7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG1O|E6OTJpPkKxOVcyQTF{PD;hQi=>
C41 MoX0SpVv[3Srb36gZZN{[Xl? Mn\STY5pcWKrdHnvckBw\iCSQWLQNUBqdiCqdX3hckBEPDFiY3XscJMtKEWFNUCgQUAxNjByMjFOwG0v MmPNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlzNEO1OlkoRjF7MUSzOVY6RC:jPh?=
LoVo MUnGeY5kfGmxbjDhd5NigQ>? MoDhN|AhdWmwcx?= MoPwTY5pcWKrdHnvckBw\iCSQWLQJIlvKGi3bXHuJGxwXm9iY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBxd2y7KFHEVEkuemmkb4PlJJBwdHmvZYLpfoF1cW:wIH\vdkA{OCCvaX7zJIJ6KG[udX;y[ZNk\W6lZTDhd5NigSxiRVO1NEA:KDBwMEC1PVQh|ryPLh?= M{nNUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyO|E4Lz5{Nk[1NlcyPzxxYU6=
LoVo M1PUZWZ2dmO2aX;uJIF{e2G7 M33WeVMxKG2rboO= MYnJcohq[mm2aX;uJI9nKFCDUmCgbY4hcHWvYX6gUI9XdyClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJBwdHlqQVTQLU1zcWKxc3WgdI9tgW2ncnn6ZZRqd25iZn;yJFMxKG2rboOgZpkh\my3b4Lld4NmdmOnIHHzd4F6NCCHQ{WwJF0hOC5yMEW5OEDPxE1w NUXsbWdJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2OVI4OTdpPkK2OlUzPzF5PD;hQi=>
LoVo Moj4SpVv[3Srb36gZZN{[Xl? NGjx[Vk{OCCvaX7z NHy2R3RKdmirYnn0bY9vKG:oIGDBVnAhcW5iaIXtZY4hVG:YbzDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHCxbImoRWRRMS2{aXLvd4UheG:ueX3ldol7[XSrb36g[o9zKDNyIH3pcpMh[nliZnz1c5Jme2OnbnPlJIF{e2G7LDDFR|UxKD1iMD6wNFU6PCEQvF2u NXHzcmxsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2OVI4OTdpPkK2OlUzPzF5PD;hQi=>
VC8 M1T6OGN6fG:2b4jpZ4l1gSCjc4PhfS=> NVfKU41mOyCmYYnz NWDlOmdSS3m2b4TvfIlkcXS7IHHnZYlve3RiQ3jpcoV{\SCqYX3zeIVzKF[FODDj[YxteyCqYYLic5JqdmdiQmLDRVIh\GWoaXPp[Y51KGGodHXyJFMh\GG7czDifUBES0t6IHHzd4F6NCCFQ{WwJF0hOi5|NESg{txONg>? M4XKS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7M{O1NlA2Lz5{OUOzOVIxPTxxYU6=
LoVo MV3DfZRwfG:6aXPpeJkh[XO|YYm= MnHSNE41KHWP MnroOUBl[Xm| NXy1UHpWWG:2ZX70bYF1cW:wIH;mJJRmdW:8b3zvcYll\S2rbnT1Z4VlKGO7dH;0c5hq[2m2eTDpckBpfW2jbjDMc3ZwKGOnbHzzJIF{e2W|c3XkJIF{KHSnbX;6c4xwdWmmZTDHTVUxKGG2IECuOEB2VSCjZoTldkA2KGSjeYOgZpkhS2WubITpeIVzNUeubzDhd5NigSxiR1m1NEA:KDZwMkCzJO69VS5? MmnTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4NUK3NVcoRjJ4NkWyO|E4RC:jPh?=
A673 M3PINZFJXFNiYYPzZZk> M3zRT5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy| Ml60QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Saos-2 MV\xTHRUKGG|c3H5 M2HKc5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVYX;zMVIh[2WubIO= M2jjUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB1643 NYL5SnI2eUiWUzDhd5NigQ>? NWGyOJpYeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=> NFW4RXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-SH MX;xTHRUKGG|c3H5 NETzd4tyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCRcoToc4dwdmGuIEPEJJZq[WKrbHn0fUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIO= MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-MC M3u3TpFJXFNiYYPzZZk> MX;xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?= NEm2bYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
TC32 NWjiUHY{eUiWUzDhd5NigQ>? MmjSdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgWGM{OiClZXzsdy=> M4i3OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2 MnrYdWhVWyCjc4PhfS=> NE\Dc29yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCRcoToc4dwdmGuIEPEJJZq[WKrbHn0fUB{[3KnZX6g[o9zKFOMLVfCUVIh[2WubIO= NGe2XGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
EoL-1-cell NYX4eGxzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTFwMEe5PEDPxE1? MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NFY5PzFxJ{7TRW5ITVJ:L3G+
NCI-SNU-5 NXSzNGJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnDOZFKSzVyPUOuNVI5PDFizszN M3vld|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
BV-173 M3zq[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4f5Z2lEPTB;NT60OVQxQSEQvF2= MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NFY5PzFxJ{7TRW5ITVJ:L3G+
HCC1806 NYT5bJVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTVwN{WxO|Mh|ryP NYfsZ5JrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTB4OEexM{c,W0GQR1XSQE9iRg>?
COLO-680 NHXvflZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH25VWpKSzVyPU[uNlE1ODZizszN NV;hOVl[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTB4OEexM{c,W0GQR1XSQE9iRg>?
HCC2218 M4\2U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTdwN{m3NFQh|ryP MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NFY5PzFxJ{7TRW5ITVJ:L3G+
SK-MEL-24 M{j1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPnW3FKSzVyPUeuPFE6OjRizszN NITxVII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2ODZ6N{GvK|5USU6JRWK8M4E,
NCI-H720 NHqycGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjx[IVsUUN3ME24MlQ{PjB|IN88US=> NVXpZXJqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTB4OEexM{c,W0GQR1XSQE9iRg>?
KASUMI-1 Ml\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfx[IhpUUN3ME24Mlg6OjZ4IN88US=> NFe2fZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2ODZ6N{GvK|5USU6JRWK8M4E,
HAL-01 MknhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTlwOEi2NkDPxE1? MlzxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
CAL-33 NUDRb3Z{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{L3OmlEPTB;MUCuOFM1KM7:TR?= MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NFY5PzFxJ{7TRW5ITVJ:L3G+
SK-MEL-1 MmLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jTe2lEPTB;MUKuOFY3OyEQvF2= MnXLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
Ramos-2G6-4C10 NVG4PVVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mom4TWM2OD1zMj60O|UzKM7:TR?= MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NFY5PzFxJ{7TRW5ITVJ:L3G+
KY821 M2rUdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVuyPJZXUUN3ME2xNk41QDVizszN NWi0S2RlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTB4OEexM{c,W0GQR1XSQE9iRg>?
HEC-1 M2C4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTF{LkmxPVYh|ryP MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NFY5PzFxJ{7TRW5ITVJ:L3G+
SK-NEP-1 NVfqV4JzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTF|LkG2OkDPxE1? M{\ve|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
MN-60 NFrjR4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYi2SmRZUUN3ME2xN{42Ozh7IN88US=> MkDzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
DU-145 NWDIRlNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETPZ4pKSzVyPUGzMlkxPTNizszN Mom0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
EW-3 M2LDUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPHb5FGUUN3ME2xOE42PTZ3IN88US=> M{HuV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
OS-RC-2 M3\YN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTF3Lkm1PFkh|ryP NXTrZml6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTB4OEexM{c,W0GQR1XSQE9iRg>?
RPMI-8226 M1HBeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTF4LkKwOFIh|ryP MofUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
ChaGo-K-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfz[m1DUUN3ME2xOk42OzJ3IN88US=> NWD5eY5XRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTB4OEexM{c,W0GQR1XSQE9iRg>?
DEL MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTF4Lk[3NVch|ryP M3j4XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
GP5d M{T0Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXO5eWpFUUN3ME2xO{4xPTNizszN NGiwZWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2ODZ6N{GvK|5USU6JRWK8M4E,
COLO-668 M3XmcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnkbWVKSzVyPUG3MlYzQTRizszN MlnUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
H9 MmnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFyzdHBKSzVyPUG4MlI5OzNizszN NHGyUWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2ODZ6N{GvK|5USU6JRWK8M4E,
NKM-1 M3zNW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3YTWM2OD1zOD61NVE6KM7:TR?= MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NFY5PzFxJ{7TRW5ITVJ:L3G+
KYSE-150 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DY[WlEPTB;MUiuPVk5PiEQvF2= NGPEbpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2ODZ6N{GvK|5USU6JRWK8M4E,
Daoy MonuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlGxTWM2OD1zOT61OlQ6KM7:TR?= M2G3e|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
ECC10 NGWyTlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIm2OZNKSzVyPUKwMlc1PTVizszN MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NFY5PzFxJ{7TRW5ITVJ:L3G+
A388 M{Lm[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTJzLkmwPVEh|ryP M1HhZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
MHH-NB-11 M1T1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DQVmlEPTB;MkOuNVM3OyEQvF2= M2r4NFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
HCC1937 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLOV29KUUN3ME2yOE44PDZizszN M{G3XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
TGBC11TKB MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjCTWM2OD1{NT62PFY{KM7:TR?= NFv1bo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2ODZ6N{GvK|5USU6JRWK8M4E,
CTV-1 MmmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVyydVhjUUN3ME2yOU45QTZ7IN88US=> M2LqeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
NCI-H2029 NULiW3dRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE[z[XhKSzVyPUK2MlQzOzhizszN MlLyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
HLE NX3VdnlnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkL6TWM2OD1{Nz6wOVQh|ryP M2P1N|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
NCI-H1693 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHnTWM2OD1{Nz6yPFk5KM7:TR?= NXLsV5dwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTB4OEexM{c,W0GQR1XSQE9iRg>?
HCC70 M1HyTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn34TWM2OD1{Nz63NlQ3KM7:TR?= MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NFY5PzFxJ{7TRW5ITVJ:L3G+
BEN NFHTOlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTJ5Lkm1OlYh|ryP MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NFY5PzFxJ{7TRW5ITVJ:L3G+
LB771 MmnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPrTWM2OD1{OD64N|c{KM7:TR?= MnjpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
697 M2fCVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTJ7LkCyN|Uh|ryP NGHPZWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2ODZ6N{GvK|5USU6JRWK8M4E,
LU-139 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nsOmlEPTB;MkmuN|c1QCEQvF2= MlPrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
EW-13 M4HyPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkiwTWM2OD1{OT6zPFE1KM7:TR?= Mm\iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
MOLT-13 NGLQU5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGD2N5RKSzVyPUK5MlM5OTRizszN NYjGUmh4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTB4OEexM{c,W0GQR1XSQE9iRg>?
L-363 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3X5cmlEPTB;MkmuOFc6QCEQvF2= MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NFY5PzFxJ{7TRW5ITVJ:L3G+
EM-2 NF\sXFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;ReGlEPTB;MkmuOFkxOSEQvF2= NFKwPHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2ODZ6N{GvK|5USU6JRWK8M4E,
RS4-11 MkHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTNyLkSyOFEh|ryP NF\mbXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2ODZ6N{GvK|5USU6JRWK8M4E,
A2780 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknKTWM2OD1|MD63OFU4KM7:TR?= NX3ySXhjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTB4OEexM{c,W0GQR1XSQE9iRg>?
KU812 M{XufWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljlTWM2OD1|Mj6zOlQzKM7:TR?= NI\OUI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2ODZ6N{GvK|5USU6JRWK8M4E,
COLO-684 MlfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTN|LkO1PVkh|ryP MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NFY5PzFxJ{7TRW5ITVJ:L3G+
MFE-280 M3foTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LCdWlEPTB;M{OuN|g5QSEQvF2= NUW3cpU5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTB4OEexM{c,W0GQR1XSQE9iRg>?
KG-1 NH\3[JFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfUZY1KSzVyPUOzMlYxODFizszN M{DZPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
JVM-3 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTN3LkW4Olgh|ryP NIXCVHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2ODZ6N{GvK|5USU6JRWK8M4E,
MV-4-11 MoP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;Yc2lEPTB;M{WuPFQ6QSEQvF2= NHrhbmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2ODZ6N{GvK|5USU6JRWK8M4E,
LAMA-84 NH;ZXG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M371[mlEPTB;M{[uO|M1PSEQvF2= MnraQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
MOLT-16 NYrCepdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTN4Lkm1NkDPxE1? NV;IXIFsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTB4OEexM{c,W0GQR1XSQE9iRg>?
H4 NV74dVNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zhdmlEPTB;M{euOVY4KM7:TR?= MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NFY5PzFxJ{7TRW5ITVJ:L3G+
T47D MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2C4[mlEPTB;M{euO|AyQCEQvF2= MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NFY5PzFxJ{7TRW5ITVJ:L3G+
CAL-54 NIPVXmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnIbmFoUUN3ME2zO{46PjZizszN M{TWc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
SW982 M{PwfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTN6LkC5PVgh|ryP Mk\rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVA3QDdzLze+V2FPT0WUPD;hQi=>
IGROV-1 M{TWeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfSeGZKSzVyPUO5MlM{ODRizszN MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NFY5PzFxJ{7TRW5ITVJ:L3G+
NB14 NXvRd3dGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLlTWM2OD12MD63NFMyKM7:TR?= MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NFY5PzFxJ{7TRW5ITVJ:L3G+
HCC1187 M3;4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrVTWM2OD12MT6yO|cyKM7:TR?= MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NFY5PzFxJ{7TRW5ITVJ:L3G+
SBC-1 NE\5OpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37wOWlEPTB;NEGuN|A3OyEQvF2= NH7GZWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2ODZ6N{GvK|5USU6JRWK8M4E,
KARPAS-45 NYe5NI1wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzSelFvUUN3ME20NU41QDF6IN88US=> NWrkSZRLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTB4OEexM{c,W0GQR1XSQE9iRg>?
MOLT-4 NHXlcXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTR{LkK1N|gh|ryP MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NFY5PzFxJ{7TRW5ITVJ:L3G+
JVM-2 Ml3SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTR{LkmyNFch|ryP MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NFY5PzFxJ{7TRW5ITVJ:L3G+
A4-Fuk M1nES2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fzNmlEPTB;NEOuOVY6OSEQvF2= NGexb489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2ODZ6N{GvK|5USU6JRWK8M4E,
MDA-MB-361 NVLDfoJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\LbmFMUUN3ME20N{45PDF2IN88US=> M{jPOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
BALL-1 NVjETHlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHDTWM2OD12Mz65OVMzKM7:TR?= M1Tue|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
T98G NFzCUYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXoUWdwUUN3ME20OE45PTF5IN88US=> NXPW[pRxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTB4OEexM{c,W0GQR1XSQE9iRg>?
Mo-T NGSye2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTR3Lk[zPFkh|ryP MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1NFY5PzFxJ{7TRW5ITVJ:L3G+
MHH-PREB-1 NVWzZlJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjzTWM2OD12NT63OVg2KM7:TR?= M1L4VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFUxPjh5MT:nQnNCVkeHUkyvZV4>
ALL-PO MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXFTWM2OD12Nz6zO|kyKM7:TR?= NFTVPW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2ODZ6N{GvK|5USU6JRWK8M4E,
NCI-H510A M{myW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3pZXBKSzVyPUS3MlkxOzRizszN NIDGflA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2ODZ6N{GvK|5USU6JRWK8M4E,
ML-2 NWnrTIVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2T6emlEPTB;NEmuO|g2PiEQvF2= NVfM[oZbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTB4OEexM{c,W0GQR1XSQE9iRg>?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-STAT3 / STAT3 / p-AKT(S473) / p-AKT(T308) / p-ERK / p-p38; 

PubMed: 22678161     


Effects of AG-014699, AZD-2281, ABT-888, or BSI-201 on the phosphorylation status of Stat3, Akt, ERK, and p38 in MDA-MB-468, MDA-MB-231, and Cal-51 cells after 72 h of treatment

22678161
Immunofluorescence
HuR; 

PubMed: 28687616     


Immunofluorescent images of HuR (green) in MIA PaCa-2 cells treated with PARPi for 12hr. Nuclei were stained with DAPI. Magnification 40X.

BRCA1; 

PubMed: 21917757     


Effects of ABT-888 and/or bortezomib on BRCA1 and RAD51 foci formation. BRCA1 and RAD1 foci induced by ABT-888 were completely resolved in cells cotreated with bortezomib. Image acquisition was performed with an epifluorescence microscope (BX51; Olympus) and multispectral color camera (Nuance FX; CRi) with a 60× or 100× magnification lens and oil immersion.

28687616 21917757
Growth inhibition assay
Cell viability (TNBC cell lines); 

PubMed: 27880910     


BRCA-proficient TNBC cell lines were treated with veliparib in the absence and presence of dinaciclib, demonstrating reduced IC50 values in the presence of dinaciclib.

Cell viability (melanoma cells); 

PubMed: 29956724     


Dose-dependent inhibitory effect of ABT-888 on melanoma cell proliferation. Human melanoma cell lines were exposed to diluents (control; CTRL) or increasing concentrations of ABT-888 for 72 h and their viability was assessed by MTT assay. Absorbance was detected at 540 nm with a microplate reader and data were expressed as a percentage of the CTRL. Data are the means ± SD of 3 experiments performed in triplicate. Statistical significance was calculated against the CTRL (*P<0.05; **P<0.01).

27880910 29956724
In vivo The oral bioavailability of ABT-888 is 56%-92% in mice, Sprague-Dawley rats, beagle dogs, and cynomolgus monkeys after oral administration. [1] ABT-888 (25 mg/kg i.p.) could improve tumor growth delay in a NCI-H460 xenograft model with well tolerated. Combination with radiation, ABT-888 decreases the tumor vessel formation. [3] ABT-888 reduces intratumor PAR levels by more than 95% at a dose of 3 and 12.5 mg/kg in A375 and Colo829 xenograft models and the suppression could be maintained over time. [4]

Protocol

Animal Research:

[1]

- Collapse
  • Animal Models: NCI-H460, H460, B16F10 and 9L xenografts in C57BL/6 mice
  • Dosages: ~25 mg/kg
  • Administration: Orally administered
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 17 mg/mL (69.58 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
0.5% methylcellulose+0.2% Tween 80
For best results, use promptly after mixing.
5 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 244.29
Formula

C13H16N4O

CAS No. 912444-00-9
Storage powder
in solvent
Synonyms NSC 737664
Smiles CC1(CCCN1)C2=NC3=C(C=CC=C3N2)C(=O)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03044795 Withdrawn Drug: Veliparib Cancer University Medical Center Groningen|AbbVie|Dutch Cancer Society November 2019 Phase 2
NCT02723864 Active not recruiting Drug: Veliparib + VX-970 + Cisplatin Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) August 9 2017 Phase 1
NCT02483104 Completed Drug: veliparib|Drug: carboplatin|Drug: paclitaxel Ovarian Cancer AbbVie July 2015 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products

Tags: buy Veliparib (ABT-888) | Veliparib (ABT-888) supplier | purchase Veliparib (ABT-888) | Veliparib (ABT-888) cost | Veliparib (ABT-888) manufacturer | order Veliparib (ABT-888) | Veliparib (ABT-888) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID